Predicting drug safety with Bio-AI
Quris AI (quris.ai) scores 75 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, Technology brands, in the 51st percentile of 5135 Healthcare brands.
Quris AI is a healthcare technology company that develops a machine-learning bio-platform designed to predict whether drug candidates will safely work in humans. The company combines artificial intelligence with miniaturized Patients-on-a-Chip technology to generate biological data used for drug safety prediction. Quris AI positions itself as an AI safety prediction platform for the pharmaceutical industry, aiming to reduce the high failure rate of clinical trials. Its target audience includes pharmaceutical companies, drug developers, and biotech researchers.
| Brand Name | Quris AI |
|---|---|
| Domain | quris.ai |
| Industry | Healthcare, Technology |
| Main Competitors | Insilico Medicine (83/100), Recursion Pharmaceuticals (85/100), Emulate, BenevolentAI, Exscientia, Cellarity (67/100), Atomwise (78/100) |
Moz Domain Authority 31/100 vs category average 38 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Quris AI is tackling the most impactful AI challenge of our time: Predicting which drug candidates will safely work in humans. Quris’s machine-learning bio-platform predicts which …" (Meta description: 33 words. OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 3 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Wix, React.
Social footprint: verified profiles on LinkedIn, X (Twitter), Instagram, YouTube, GitHub; no detected presence on Facebook - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is Quris AI?", Claude could identify the brand as of September 2026. Quris AI is a biotech startup that combines organ-on-a-chip technology with artificial intelligence to predict how experimental drugs will behave in humans before clinical trials begin, aiming to reduce drug development costs and failure rates. Their platform uses patient-derived Best known for AI-powered organ-on-a-chip technology for predicting clinical drug safety and efficacy before human trials.
When asked "Best brands similar to Quris AI?", Claude would recommend Quris AI as of September 2026. It's a notable player in the AI drug discovery and preclinical testing space, so it would come up in discussions of companies bridging biotech and AI for faster, cheaper drug development.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Quris AI's main competitors in Healthcare: Insilico Medicine (83/100), Recursion Pharmaceuticals (85/100), Cellarity (67/100), Atomwise (78/100).
Sources: Brand Analyzer scan
Quris AI has limited AI-search visibility, scoring 34/100 on Brand Analyzer's AI visibility composite (visibility 17, trust 49, recommendation 45). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Quris AI official site
Quris AI scores 45/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Quris AI official site
Quris AI offers a machine-learning bio-platform that predicts the safety of drug candidates for human use. The platform integrates AI models with data generated from miniaturized Patients-on-a-Chip technology, producing automatically-tagged biological datasets intended to improve the accuracy of drug safety predictions and reduce clinical trial failure rates.
Sources: Quris AI official site
Quris AI is a healthcare technology company that has developed a machine-learning bio-platform aimed at predicting whether drug candidates will safely work in humans. It combines artificial intelligence with miniaturized Patients-on-a-Chip technology to generate biological data used to assess drug safety before clinical trials.
Sources: Quris AI official site
Quris AI predicts which drug candidates are likely to be safe for human use by combining machine learning with Patients-on-a-Chip technology. This hybrid AI-and-biology approach generates automatically-tagged biological data that is used to model drug safety, with the goal of reducing the high failure rate seen in clinical trials.
Sources: Quris AI official site
Quris AI can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Quris AI official site
Quris AI's platform is intended for use by pharmaceutical companies, drug developers, and biotech researchers who are seeking to improve the prediction of drug safety and reduce the rate of clinical trial failures.
Sources: Quris AI official site
Quris AI is known for developing an AI-driven drug safety prediction platform that integrates machine learning with miniaturized Patients-on-a-Chip technology. The company positions itself as one of the first in the pharmaceutical AI space to specifically address the problem of predicting clinical trial safety outcomes, rather than focusing solely on drug discovery or design.
Sources: Quris AI official site
Quris AI scores 34/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Quris AI has a weak AI-visibility profile at 34/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is trust (49/100) and its weakest is visibility (17/100). It benefits from a Wikidata knowledge-graph entry, open access for AI crawlers (GPTBot, ClaudeBot, etc.) and machine-readable schema.org markup. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data and a low Moz Domain Authority of 31/100. In a live check, Claude could already identify Quris AI from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Quris AI: PursueCare (75/100), Providence (75/100), The Royal College of Surgeons of England (75/100), Recordati (75/100).
A step up - brands to learn from: Zurich Insurance Group (81/100), Zeel (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.